Using computerized databases, references lists, and expert recommendations, DeCamp et al identified 11 prospective controlled studies that met inclusion criteria. The 11 articles evaluated 7 different antiemetics, including ondansetron (n = 6), domperidone (n = 2), trimethobenzamide (n = 2), pyrilamine-pentobarbital (n = 2), metoclopramide (n = 2), dexamethasone (n = 1), and promethazine (n = 1). The 6 studies evaluating ondansetron, a 5-hydroxytryptamine antagonist commonly used for the treatment of postoperative or chemotherapy-associated nausea and vomiting, included 774 children with a clinical diagnosis of GE. In a meta-analysis, children who received ondansetron treatment were less likely to have ongoing vomiting, be prescribed IVFs, or be admitted to the hospital from the emergency department (ED). However, diarrhea was increased in children receiving ondansetron treatment. The articles evaluating domperidone, trimethobenzamide, pyrilamine-pentobarbital, metoclopramide, dexamethasone, and promethazine had small sample sizes, were of low methodological quality, and produced inconsistent results. Meta-analyses were, therefore, not done to evaluate these antiemetics, nor do DeCamp et al recommend their use. Overall, DeCamp et al conclude that ondansetron treatment is beneficial in moderately ill children with acute GE.